Background: Metastasis-associated with colon cancer-1 (MACC1) is an important regulator that promotes colorectal cancer (CRC) cells' proliferation and distant metastasis. Therefore, MACC1 is considered as a promising therapeutic target of CRC. This work aimed to identify the microRNA (miR) targeted to MACC1, and to study the potential of using the particular miR in enhancing the antitumor effect of chemotherapy. Materials and methods: miR prediction was performed in the miR database. The effect of miR-940 on MACC1's expression was examined by Western blot, and the effect of miR-940 on the expression of genes related to the epithelial-mesenchymal transition (EMT) was identified by quantitative real-time polymerase chain reaction experiments. In vivo growth of CRC cells were analyzed in the nude mice subcutaneous tumor model and CRC liver metastasis model. Results: By using the database, miR-940 was identified to target to the 3ʹUTR of MACC1's mRNA. Experimentally, transfection of miR-940 decreased the expression of MACC1 in CRC cells and inhibited the EMT process of the transfected cells. MiR-940 also enhanced the inhibitory effect of Anlotinib on CRC cells' in vivo growth and invasion. Correspondingly, ectopic expression of MACC1 mutant, which does not contain miR-940 binding site, blocked the antitumor effect of miR-940 on CRC cells. Conclusion: MiR-940 restricts the proliferation and invasion of CRC cells by targeting to MACC1's mRNA, and enhances the antitumor effect of Anlotinib on CRC tumors.
Introduction
Colorectal cancer (CRC) is a common malignant tumor in the digestive tract, and its mortality ranks third in all malignancies. 1, 2 In China, the incidence of CRC has increased year by year, with an average annual rate of 4-5%. In 2015, the number of new cases of and deaths caused by CRC has doubled compared with 10 years ago, reaching 377,000 and 191,100 cases, respectively. 3 In recent years, with the continuous development of clinical diagnosis and treatment approaches, the prognosis of patients with primary CRC has improved and the median survival has prolonged. 4, 5 However, the prognosis of advanced CRC, especially with liver metastasis, is still very poor; the 5-year survival rate is only 1-2%. [6] [7] [8] Thus, treating advanced CRC is a strong challenge. There are advances in treating CRC liver metastases, such as chemotherapeutic options include CAPOX, 9 ,10 FOLFOX4 11,12 and FOLFIRI 13, 14 that alleviated disease progression, achieved degraded patient behavior scores which ultimately made surgical resection realizable. However, only 30-40% of patients can be benefited from antitumor chemotherapies due to the low response rate. 7 Therefore, establishing more effective antitumor treatment strategies for CRC is of great clinical significance. Metastasis-associated in colon cancer-1 (MACC1) is an important regulator that, as multiple works reported, promotes CRC cells' proliferation and enhances the distant metastasis. 15, 16 Increasing evidence has revealed that a high level of MACC1 expression in clinical specimens is significantly associated with poor patient survival. 17, 18 Moreover, MACC1 participates in regulating drug resistance: Li et al (2015) reported that downregulation of MACC1 attenuated cisplatin resistance in tongue squamous cell carcinoma. 19 Zhang et al (2016) showed that knockdown of MACC1 overcame the resistance of cisplatin in the cisplatin-resistant epithelial ovarian cancer cell line. 20 Duan et al (2017) indicated that MACC1 induces the chemotherapeutic-resistance of gastric cancer cells by regulating FASN expression. 21 Therefore, MACC1 is a promising therapeutic target to reduce chemotherapy resistance. This work screened microRNAs (MiRs) and found miR-940 targeted to MACC1. We then showed miR-940 restricts the proliferation and invasion of CRC cells. Anlotinib is a newly approved orally administrative small-molecule receptor tyrosine kinases (RTK) inhibitor that targets to RTKs related to tumor proliferation and metastasis, including vascular endothelial growth factor receptor, c-proto-oncogene protein, platelet-derived growth factor receptor or fibroblast growth factor receptors. 22, 23 The low response rate in patients indicating the efficiency of Anlotinib need to be enhanced by certain means, although the effect of this agent revealed to be promising in rodent models. 22, 24 In the present work, we found miR-940 enhanced the antitumor effect of Anlotinib on CRC tumors. For the in situ colorectal tumor model, nude mice received inhalation anesthesia. Cells were transfected with miRNA-940 or miR-940+ mutated MACC1 (MACC1 Mut ). The roving sandpaper was used to injure the anus, and the rectum was filled with cell suspensions. Next, the anus was clamped with a small clip for 15-20 mins. Three to four days after cells were injected, the mice received oral administration of 1 mg/kg dose Anlotinib per two days. After 3-4 weeks' growth, the mice were harvested, and tumor weights were measured. Tumor volumes were calculated following the methods provided by and Chen et al (2018) . 27, 28 To produce a liver in situ tumor model, SW620 cells that had been transfected with vectors were seeded into the livers of nude mice, following a method described by Meng et al (2018) . 29 The liver organs with nodules formed by the MDA-MB-231 cells were collected for Masson staining using a standard method. Masson staining results were quantitatively analyzed, following the methods described by Shao et al (2018) . 30 
Material and methods

Cell lines and agents
qPCR experiments
The total RNA (Ribonucleic Acid) of cells or clinical specimens was extracted using a PARISTM Kit (Applied Biosystems, Thermo Scientific Corporation, Waltham, MA, USA) and were reverse-transcribed by Multiscribe TM Reverse Transcriptase (Applied Biosystems, Thermo Scientific Corporation). The qPCR (real-time polymerase chain reaction/Quantitative polymerase chain reaction) experiments were performed as described previously. [31] [32] [33] The level of GAPDH mRNA was measured as an internal control. Primers used in qPCR are shown in Table 1 .
Statistical analysis
All statistical significance analyses were performed using SPSS 16.0 statistical software (IBM Corporation, Armonk, NY, USA 
Results
MiR-940 restricts MACC1's expression by targeting the 3′-UTR of MACC1's mRNA
To identify the potential miRNA targeting MACC1, the miR database was used. As shown in Figure 1 , miR-940 was found to target MACC1's mRNA with a high score ( Figure 1A and B). The expression of MACC-1 and miR-940 was examined in clinical specimens. As shown in Figure S1 , MACC1 is expressed higher in tumor tissues compared with non-tumor controls; MACC1 has the highest expression level In CRC samples. Interestingly, the Table 1 The primers used in this work performed. As shown in Figure S3 , miR-940 inhibited the luciferase activity of a reporter promoter contains miR-940 target sites. Therefore, miR-940 targets to MACC1.
MiR-940 inhibits CRC cells' EMT process
Next, the effect of miR-940 on migration and invasion-related pathways were examined. As shown in Figure 2 , transfection of miR-940 inhibited the expression of N-cadherin and Vimentin, two mesenchymal indicators, and enhanced the expression of E-Cadherin, an epithelial indicator. These results showed that miR-940 inhibited the EMT process of CRC cells. Transfection of miR-940's inhibitor or overexpressing MACC1 Mut blocked the effect of miR-940 on EMT.
Therefore, miR-940 inhibits CRC cells' EMT process by targeting MACC1.
MiR-940 enhances the antitumor activation of Anlotinib on CRC cells
MTT were performed to examine whether targeting MACC1 could enhance the sensitivity of CRC cells to Anlotinib. As shown in Figure 3 and Table 2 
Discussion
Despite the advances in treatment options in recent years, CRC is still a fatal disease with increasing incidence worldwide. 34, 35 In the past two decades, systemic chemotherapy b one of the foremost choices for advanced CRC treatment. 36 Recently, molecule-targeted agents, such as cetuximab, 37 panitumumab, 38, 39 bevacizumab, 40 regorafenib 41, 42 and ramucirumab, 43, 44 that inhibit RTKs activation have been approved for use in CRC treatment. Downregulation of RTKs' activity can attenuate tumor cell growth, metastasis, and angiogenesis. [45] [46] [47] Anlotinib is newly approved and has shown an antitumor effect against several cancers, such as advanced medullary thyroid cancer, metastatic renal cell carcinoma, advanced non-small cell lung cancer (NSCLC), and advanced soft tissue sarcoma.- 48, 49 In the present work, we showed that Anlotinib inhibited the proliferation and invasive growth of CRC cells. Our data extended the understanding of Anlotinib in treating human cancers. It is well known that MACC1 participates in the regulation of cancer cell proliferation and metastasis that mediate poor clinical outcomes. 50 Recently, MACC1 was also found to be a showed that high levels of MACC1 predict poor outcomes of cryoablation therapy for advanced HCC. 51 Liu et al (2016) revealed a new mechanism of MACC1-mediated trastuzumab resistance in gastric cancer. They found MACC1 promotes trastuzumab resistance via modulating PI3K/AKT signaling pathway and inducing the Warburg effect on gastric cancer cells. 52 Moreover, Wang et al (2017) reported that MACC1
facilitates the chemoresistance of CRC cells by inducing the cancer stem cell-like properties of CRC cells. 53 In the present work, we showed downregulation of MACC1 expression via miR-940 enhanced the antitumor effect of Anlotinib on CRC cells' proliferation and invasive growth. Mechanism studies showed that overexpression of miR-940 inhibited the EMT process of CRC cells. Inhibition of the EMT could enhance the sensitivity of human cancer cells to therapeutic strategies, such as sorafenib and radiofrequency ablation. [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] Therefore, miR-940 is a promising approach to enhance the sensitivity of CRC cells to Anlotinib.
The liver metastasis is closely related to the poor prognosis of CRC patients. 58, 59 To mimic CRC liver metastasis, we established an intrahepatic invasion model. In the present work, we found CRC cells were adhered to the surface of the liver, destroyed the liver capsule and allows CRC cells to invade the liver tissue. The degree of CRC cells' invasive growth into the liver tissue can quantitatively reflect the metastasis of the tumors. This model is more representative and efficient to mimic the in vivo invasion of human cancer cells compared to other tumor metastasis model: tumor cells were injected through tail-vein injection to form tumor nodules in nude mice's lung organs. 32, 33 The massive capillary system in the lung allows cells to locate in the entire organ, but the pathological invasion of cells cannot be simply mimicked in this model. Therefore, our model is a useful tool to evaluate the therapeutic effect of antitumor therapies on cancer cells' invasive growth. MiRs are non-coding RNAs and very important components of the post-transcriptional regulation of the gene expression profile. 59 MiRs are promising tools to attenuating the metastasis of human cancer cells. 61, 62 MiR-940 is a potential negative regulator of human cancer cells. Gu et al (2018) reported that transfection of MiR-940 inhibits the progression of NSCLC by targeting FAM83F. 63 Wang et al (2017) showed that miR-940 suppresses cell proliferation of ovarian cancer OVCAR3 cells. 64 OncoTargets and Therapy
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